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Abstract. 
 
Neuropilin-1 (NRP1) is a receptor for two 
unrelated ligands with disparate activities, vascular en-
dothelial growth factor-165 (VEGF
 
165
 
), an angiogenesis 
factor, and semaphorin/collapsins, mediators of neu-
ronal guidance. To determine whether semaphorin/col-
lapsins could interact with NRP1 in nonneuronal cells, 
the effects of recombinant collapsin-1 on endothelial 
cells (EC) were examined. Collapsin-1 inhibited the 
motility of porcine aortic EC (PAEC) expressing NRP1 
alone; coexpressing KDR and NRP1 (PAEC/KDR/
NRP1), but not parental PAEC; or PAEC expressing 
KDR alone. The motility of PAEC expressing NRP1 
was inhibited by 65–75% and this inhibition was abro-
gated by anti-NRP1 antibody. In contrast, VEGF
 
165
 
 
stimulated the motility of PAEC/KDR/NRP1. When 
VEGF
 
165
 
 and collapsin-1 were added simultaneously to 
PAEC/KDR/NRP1, dorsal root ganglia (DRG), and 
COS-7/NRP1 cells, they competed with each other in 
EC motility, DRG collapse, and NRP1-binding assays, 
respectively, suggesting that the two ligands have over-
lapping NRP1 binding sites. Collapsin-1 rapidly dis-
rupted the formation of lamellipodia and induced de-
polymerization of F-actin in an NRP1-dependent 
manner. In an in vitro angiogenesis assay, collapsin-1 
inhibited the capillary sprouting of EC from rat aortic 
ring segments. These results suggest that collapsin-1 can 
inhibit EC motility as well as axon motility, that these 
inhibitory effects on motility are mediated by NRP1, 
and that VEGF
 
165
 
 and collapsin-1 compete for NRP1-
binding sites.
Key words: angiogenesis • chemotaxis • KDR • neu-
ronal guidance • growth cones
 
V
 
ASCULAR
 
 endothelial growth factor (VEGF)
 
1
 
 is a
potent mitogenic and chemotactic factor for en-
dothelial cells (EC) in vitro and an angiogenesis
factor in vivo (Klagsbrun and D’Amore, 1996; Iruela-
Arispe and Dvorak, 1997; Korpelainen and Alitalo, 1998;
Ferrara et al., 1998; Neufeld et al., 1999). Recently, we
identified neuropilin-1 (NRP1) as a receptor for VEGF,
which is expressed on the surface of EC and tumor cells
(Soker et al., 1998). NRP1 is the third VEGF receptor de-
scribed following KDR/Flk-1 and Flt-1, but differs from
these two in that it binds VEGF
 
165
 
 but not VEGF
 
121
 
.
VEGF
 
165
 
 binds to NRP1 via the VEGF exon 7-encoded
domain that is lacking in VEGF
 
121
 
 (Soker et al., 1996,
1997), whereas Flt-1 and KDR/Flk-1 bind VEGF via the
exon 3- and 4-encoded domains, respectively (Keyt et al.,
1996). There is some evidence that NRP1 may be a media-
tor of angiogenesis. Coexpression of NRP1 and KDR in
porcine aortic EC (PAEC) enhanced VEGF
 
165
 
 binding to
KDR and the chemotactic activity of VEGF
 
165
 
 for these
cells, compared with PAEC expressing KDR alone (Soker
et al., 1998). These results suggest that in EC, NRP1 might
be acting as a coreceptor that enhances VEGF
 
165
 
-induced
activities mediated by KDR. Overexpression of NRP1 in
mice resulted in excess capillary and blood vessel forma-
tion and hemorrhaging in the embryo, contributing to em-
bryonic lethality (Kitsukawa et al., 1995). Targeted disrup-
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tion of NRP1 resulted in embryonic lethality, attributable
to unspecified defects in the cardiovascular system (Kit-
sukawa et al., 1997).
NRP1 was first described as a cell surface glycoprotein
expressed on axons in the developing nervous system
(Takagi et al., 1987, 1991, 1995; Fujisawa et al., 1995, 1997;
Satoda et al., 1995). It was suggested that NRP1 was in-
volved in neuronal cell recognition, axonal growth, and
fasciculation in particular neuronal circuits (Kawakami et
al., 1996). Targeted disruption of the NRP1 gene in mice
resulted in severe abnormalities in the trajectory of the
cranial and spinal efferent fibers that express NRP1 nor-
mally (Kitsukawa et al., 1997). Overexpression of NRP1 in
mice resulted in sprouting and defasciculation of nerve fi-
bers (Kitsukawa et al., 1995). Recently, it was demon-
strated that NRP1 is a receptor for the semaphorins (He
and Tessier-Lavigne, 1997; Kolodkin et al., 1997). Mam-
malian semaphorins and their chick homologues, the col-
lapsins, are a family of transmembrane or secreted glyco-
proteins present in neuronal and nonneuronal tissues that
act as mediators of neuronal guidance (Luo et al., 1993;
Tessier-Lavigne and Goodman, 1996; Kolodkin, 1996;
Kolodkin and Ginty, 1997). Secreted collapsin-1 (Sema
III/Sema D) acts as a localized repulsive cue that steers
sensory growth cones away from the collapsin source and
induces the collapse of dorsal root ganglia (DRG) neu-
ronal growth cones (Luo et al., 1993). The collapsin/sema-
phorin repulsive effects on neurons are mediated by bind-
ing to NRP1 as demonstrated by the abrogation of these
effects by anti-NRP1 antibodies (He and Tessier-Lavigne,
1997; Kolodkin et al., 1997). Targeted disruption of Sema
III resulted in inappropriate projection of sensory neurons
into the spinal cord where Sema III is normally expressed
(Behar et al., 1996).
These results demonstrate that NRP1 binds two ligands
that appear to have opposing effects on motility. In neu-
ronal cells, NRP1 binds semaphorin/collapsins that inhibit
the motility of axons. In EC, NRP1 binds VEGF
 
165
 
 and
acts as a coreceptor for KDR by enhancing KDR-medi-
ated chemotaxis. Since EC express NRP1, we wanted to
determine whether collapsin-1 would be active in a non-
neuronal cell by binding to EC and affecting EC motility
via NRP1. Furthermore, since collapsin-1 and VEGF
 
165
 
bind to the same receptor, NRP1, we wanted to determine
whether they competed with each other in functional EC
and DRG assays. In this report, we demonstrate that re-
combinant collapsin-1 binds to EC via NRP1 and inhibits
EC motility in an NRP1-dependent manner. It prevents
formation of lamellipodia and depolymerizes F-actin, re-
sulting in disorganization of the EC cytoskeleton, consis-
tent with its effects on the growth cone cytoskeleton (Luo
et al., 1997). Collapsin-1 and VEGF
 
165
 
 compete with each
other in EC motility, DRG collapse, and NRP1-binding
assays, suggesting there is overlap in the NRP1 binding
sites of the two ligands. In an in vitro angiogenesis assay,
collapsin-1 inhibits EC sprouting and microvessel tube for-
mation in aortic segments embedded in collagen gels. We
conclude that collapsin-1 can inhibit not only axon motil-
ity, but EC motility as well, and that the inhibition is medi-
ated by NRP1. Our results support the hypothesis that reg-
ulators of neuronal guidance may also be regulators of
angiogenesis. 
 
Materials and Methods
 
Materials
 
Human fibroblast growth factor-2 (FGF-2) and VEGF were generous
gifts from Dr. Judith Abraham (Scios Inc., Sunnyvale, CA). Anti-NRP1
antibodies raised against rat NRP1 (Kolodkin et al., 1997) were kindly
provided by Dr. Alex Kolodkin (Johns Hopkins University School of
Medicine, Baltimore, MD). Cell culture media and lipofectamine were
purchased from Life Technologies, Inc. Hygromycin B and protease in-
hibitors were purchased from Boehringer Mannheim. [
 
3
 
H]thymidine,
[
 
125
 
I]sodium, [
 
32
 
P]dCTP, and GeneScreen-Plus hybridization transfer
membranes were purchased from DuPont-NEN. Disuccinimidyl suberate
(DSS) and IODO-BEADS were purchased from Pierce Chemical Co.
RNAzol-B was purchased from TEL-TEST. DNA labeling kits were pur-
chased from Nycomed Amersham Inc. Restriction endonucleases and li-
gase were purchased from New England Biolabs. X-ray films were pur-
chased from Eastman Kodak. Recombinant human fibronectin, Falcon
 
®
 
CultureSlide, and other tissue culture ware were purchased from Becton
Dickinson. All other chemicals were purchased from Sigma Chemical Co.,
unless otherwise mentioned.
 
Cell Culture
 
Parental PAEC and PAEC expressing KDR (PAEC/KDR) were kindly
provided by Dr. Lena Claesson-Welsh (University of Uppsala, Uppsala,
Sweden; Waltenberger et al., 1994). The establishment of PAEC express-
ing NRP1 (PAEC/NRP1) and PAEC expressing KDR and NRP1 (PAEC/
KDR/NRP1) were previously described by Soker et al. (1998). These cell
lines were grown in F-12 medium containing 10% FCS, glutamine, penicil-
lin, and streptomycin. Clones of rat aortic EC (RAEC) were harvested from
rat aortic capillary sprouts by digesting the collagen gel with 1 mg/ml type I
collagenase (Worthington Biochemical Co.) and growing the cells in com-
plete DME, 1 g/liter glucose. FGF-2 (1 ng/ml) was added to the culture ev-
ery other day. Colonies exhibiting typical EC cobblestone monolayer mor-
phology were selected and subcultured. The identity of the cells as EC was
confirmed by immunostaining for von Willebrand factor and by their mito-
genic response to VEGF. Cells at passage 4–8 were used in experiments.
 
Radioiodination of Collapsin-1 and
Chemical Cross-linking
 
The radioiodination of collapsin-1 was achieved using IODO-BEADS
(Soker et al., 1998) and specific activities ranging from 40,000–100,000
cpm/ng were obtained. Cross-linking of 
 
125
 
I-collapsin-1 to PAEC was
achieved using DSS as a cross-linker in the presence of 1 
 
m
 
g/ml heparin, as
previously described (Soker et al., 1998). Cross-linked complexes were re-
solved by 6% SDS-PAGE and the gels were exposed to X-ray films.
 
AP-VEGF
 
165
 
 Production and Cell Binding
 
The preparation of alkaline phosphatase (AP)-VEGF
 
165
 
 fusion protein
and its binding to NRP1-transfected COS-7 cells was carried out using
methods similar to those described previously for preparing AP-collapsins
and their binding to COS-7 cells (Feiner et al., 1997). In brief, the
open reading frame (ORF) of VEGF
 
165 
 
was amplified with primers 5
 
9
 
-
AATAATGGATCCGCACCCATGGCAGAAGGAG-3
 
9
 
 and 5
 
9
 
-ATA-
TATGCGGCCGCTCACCGCCTCGGCTTGTC-3
 
9
 
, digested with BamHI
and NotI, and cloned into a modified version of pcDNA3 (PAG-NT) that
placed VEGF
 
165
 
 downstream of AP containing a signal sequence. To pre-
pare recombinant AP-VEGF
 
165
 
, 293T cells grown to 
 
z
 
70% confluency
were transfected with 50–60 
 
m
 
g plasmid per 150-mm dish using calcium
phosphate precipitation, and conditioned medium (CM) was collected. To
quantitate AP-VEGF
 
165
 
, supernatants were assayed for AP activity. The
amount of AP activity in CM was titrated to correspond to the activity of
known amounts of AP. For binding experiments, stable COS-7 cell lines
expressing NRP1 (COS-7/NRP1) were established by transfection of
NRP1 cDNA in a PAG-NT vector and selection with G418. The COS-7/
NRP1 cells in 48-well plates were incubated with serial dilutions of 293T
cell AP-VEGF
 
165
 
 in the absence or presence of 30 nM (
 
z
 
3 
 
m
 
g/ml)
collapsin-1 or 50 nM (
 
z
 
1.25 
 
m
 
g/ml) untagged VEGF
 
165
 
. After binding of
AP-VEGF
 
165
 
 for 1 h at room temperature, COS-7/NRP1 cells were
washed gently six times for 5 min each with PBS, fixed with 4% parafor-
maldehyde for 30 min, and washed extensively with PBS. Endogenous
AP was heat-inactivated by incubation at 72
 
8
 
C for 3 h. To measure cell- 
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bound AP-VEGF
 
165
 
, COS-7/NRP1 cells were incubated with a phos-
phatase reaction mixture consisting of 0.5 M diethanolamine, 0.25 mM
MgCl
 
2
 
, 5 mM L-homoarginine, 0.25 mg/ml BSA, 6 mM p-nitrophe-
nylphosphate for 3 h and OD
 
414
 
 was measured in a MCC340 Microplate
Spectrophotometer (Titertek Instruments).
 
Northern Analysis
 
Total RNA was prepared from cells in culture using RNAzol according to
the manufacturer’s instructions. Samples of 15 
 
m
 
g RNA were separated
on 1% formaldehyde-agarose gels and transferred to GeneScreen-Plus
membranes. The membranes were hybridized (42
 
8
 
C for 18 h) using hy-
bridization cocktails (AMRESCO) with a 
 
32
 
P-labeled fragment of rat
NRP1 cDNA corresponding to nucleotides 400–905 in the ORF. After hy-
bridization, membranes were washed and exposed to X-ray film.
 
Motility Assay
 
Motility assays were performed in a Boyden chamber (Neuro Probe Inc.)
as described previously (Elenius et al., 1997; Soker et al., 1998). In brief,
15,000 cells in serum-free medium (F12 for PAEC, DME for RAEC) con-
taining 0.1% BSA were added to wells in the upper chamber. Increasing
concentrations of collapsin-1 were added to wells in the lower chamber, in
the absence or presence of VEGF
 
165
 
 or anti-NRP1 antibody. The upper
and lower chambers were separated by a fibronectin-coated polycarbon-
ate membrane with a pore size of 8 
 
m
 
m (Corning Inc.). The number of
cells that had migrated through the filter after 4 h at 37
 
8
 
C was counted by
phase microscopy. One collapsing unit (CU) is defined as the concentra-
tion required to cause 50% collapse of DRG growth cones in culture, with
1 CU being equivalent to 
 
z
 
3 ng/ml (Luo et al., 1993). When motility to-
wards VEGF was measured, cells were serum-starved overnight to lower
baseline migration.
 
Aortic Ring Assay
 
The rat aortic ring assay was performed as described previously (Nicosia
and Ottinetti, 1990; Miao et al., 1997). In brief, thoracic aortas were ob-
tained from 3-mo-old Lewis rats. The fibroadipose tissue was carefully re-
moved under a dissecting microscope, and the aortas were sliced at 1-mm
intervals to obtain aortic rings. The aortic rings were placed on top of 0.1-
ml collagen gels in each well of a 48-well plate and a 0.2-ml collagen solu-
tion was carefully poured on top of the ring. After the gel was formed, 0.2-
ml serum-free endothelial growth medium (Life Technologies, Inc.),
which favors the growth of EC but not smooth muscle cells or fibroblasts,
was added and replaced every other day by fresh medium containing the
indicated concentration of collapsin-1. Microvessel outgrowth was visual-
ized by phase microscopy and the number of capillary vessels was counted
throughout the course of the experiment. Microvessel structure in aortic
rings previously has been characterized by light microscopy, EM, and im-
munohistochemical staining of von Willebrand factor (Nicosia and Ot-
tinetti, 1990; Miao et al., 1997).
 
Collapse Assay
 
The growth cone collapse assay using DRG isolated from E7 chick em-
bryos was performed as described in Luo et al. (1993). Collapsin-1 dose-
response curves were obtained in the presence and absence of VEGF
 
165
 
.
VEGF
 
165
 
 was resuspended in media to achieve a stock concentration of 1
mg/ml and was added to each culture to achieve a final concentration of
100 ng/ml. Purified recombinant collapsin-1 at increasing concentrations
was added to the cultures at the same time. After a 60-min incubation at
37
 
8
 
C in 5% CO
 
2
 
, the cultures were fixed in 4% paraformaldehyde in PBS
containing 10% sucrose. The tips of neurites without lamellipodia or
filopodia were scored as being collapsed.
 
Differential Interference Contrast (DIC)
Optic Microscopy
 
Cells were seeded on 8-well fibronectin-coated Falcon
 
®
 
 CultureSlides, at a
density of 5,000 cells/ml in complete tissue culture medium. At 24 h after
seeding, collapsin-1 (300 ng/ml) was added to the medium. The cells were
incubated (30 min at 37
 
8
 
C), fixed and permeabilized with 0.5% glutaralde-
hyde and 0.2% saponin in a buffer containing 10 mM MES, 150 mM NaCl,
5 mM MgCl
 
2
 
, and 5 mM glucose (2 min at 37
 
8
 
C). They were then further
fixed (8 min at 37
 
8
 
C) with 1% glutaraldehyde in the same buffer. Upon
completion of these treatments, the cells were washed twice with PBS,
fixed in 4% paraformaldehyde in PBS for 20 min, and further washed two
times with PBS and once with PBS supplemented with 0.1% BSA. Cells
were examined in a Nikon Diaphot 300 inverted microscope, using a Ni-
kon 40
 
3
 
 PlanFluor objective and Nomarsky differential interference con-
trast (DIC) optics. Digital images were captured using a Sensys KAF 1400
cooled CCD output camera (Photometrics) and controlled by an IPLab
image analysis program (Scanalytics Inc.).
 
Fluorescence Microscopy
 
RAEC were fixed for examining F-actin organization using conventional
fluorescence microscopy. In brief, cells were washed with prewarmed se-
rum-free DME, fixed, and permeabilized with prewarmed 0.5% glutaral-
dehyde, 0.2% saponin (2 min) in a cytoskeletal stabilizing (CSK) buffer
containing 50 mM NaCl, 150 mM sucrose, 3 mM MgCl
 
2
 
, 10 mM 2-ethane-
sulfonic acid, pH 6.8, which maintains the integrity of the cytoskeleton.
This solution was replaced and a second fixation step was carried out us-
ing 1% glutaraldehyde in CSK buffer for 10 min. Fixed specimens were
washed three times with CSK buffer and exposed aldehyde groups were
reduced with a freshly prepared solution of 0.5 mg/ml NaBH
 
4 
 
in CSK
buffer (40 min). After washing three times with 0.1% BSA in CSK buffer,
cell actin cytoskeleton and nuclei were stained for 60 min simultaneously
with fluorescein-labeled phalloidin (1:300; Molecular Probes) and DNA-
binding dye, 4
 
9
 
,6-diamidino-2-phenylindole (DAPI, 1 
 
m
 
g/ml; Molecular
Probes). After staining, the cells were washed extensively with 0.1% BSA
in CSK buffer (five times for 10 min each) and mounted in Fluoromount-G
(Southern Biotechnology Associates Inc.). The samples were examined in
an epifluorescence Nikon Diaphot 300 inverted microscope with a Nikon
60
 
3
 
 PlanApo oil immersion objective. Digital images were captured using
the same system.
 
Results
 
Collapsin-1 Binds to Endothelial Cells only if they 
Express Neuropilin-1 
 
NRP1 is expressed by neuronal cells and is a receptor for
members of the collapsin-1/semaphorin III family (Luo et
al., 1993; He and Tessier-Lavigne, 1997; Kolodkin et al.,
1997). To determine whether NRP1 can also function as a
receptor for collapsin/semaphorins in nonneuronal cells,
PAEC lines expressing NRP1, KDR, or both receptors
(Soker et al., 1998) were incubated with 
 
125
 
I-collapsin-1
(Fig. 1). A 100-kD protein corresponding to the size of col-
lapsin-1, and larger size proteins possibly representing col-
lapsin-1/NRP1 complexes, were detected in PAEC/NRP1
Figure 1. Cross-linking of
125I-collapsin-1.  125I-collap-
sin-1 (10 ng/ml) was bound
to subconfluent cultures of
PAEC (lane 1), PAEC/KDR
(lane 2), PAEC/NRP1 (lane
3), PAEC/KDR/NRP1 (lane
4), and MDA-MB-231 (lane 5)
cells in 6-cm dishes. The
binding was carried out in the
presence of 1 mg/ml of hep-
arin. At the end of a 2-h incu-
bation,  125I-collapsin-1 was
cross-linked to the cell sur-
face. The cells were lysed and
proteins were resolved by 6%
SDS-PAGE. The polyacryl-
amide gel was dried and exposed to X-ray film. Arrow indicates
the position of bound 125I-collapsin-1. In this experiment, nonco-
valent binding, rather than covalent cross-linking of 125I-col-
lapsin-1 to NRP1, occurred. 
The Journal of Cell Biology, Volume 146, 1999 236
 
(Fig. 1, lane 3) and PAEC/KDR/NRP1 (Fig. 1, lane 4), but
not in parental PAEC (Fig. 1, lane 1) or PAEC/KDR (Fig.
1, lane 2). These results indicated that the binding of 
 
125
 
I-
collapsin-1 to PAEC was totally dependent on the expres-
sion of NRP1. In addition, 
 
125
 
I-collapsin also bound to
MDA-MB-231 breast carcinoma cells (Fig. 1, lane 5), pre-
viously shown to express abundant NRP1 (Soker et al.,
1996, 1998).
 
Collapsin-1 Inhibits Endothelial Cell Motility 
 
Collapsin/semaphorins are inhibitors of axonal motility
acting via NRP1 (Kolodkin et al., 1997). Accordingly, the
ability of collapsin-1 to affect the motility of EC express-
ing NRP1 was tested in a Boyden chamber assay (Fig. 2).
Collapsin-1 (150 ng/ml) inhibited the motility of PAEC/
NRP1 and PAEC/KDR/NRP1 by 
 
z
 
65–70%, but did not
inhibit the motility of PAEC or PAEC/KDR at all (Fig. 2
A). The specific inhibition of only those EC expressing
NRP1 was consistent with the binding data. Collapsin-1
inhibition of PAEC/NRP1 and PAEC/KDR/NRP1 motil-
ity was dose-dependent with an ID
 
50
 
 (inhibitory dose) of
 
z
 
3 ng/ml (Fig. 2 B). A maximal inhibition of 
 
z
 
65–75%
occurred with 
 
z
 
15 ng/ml. To test whether the collapsin-
1–mediated inhibition of motility was due to repulsion,
collapsin-1 was placed in both upper and lower chambers.
The same results were found as with the presence of col-
lapsin-1 in the lower chamber alone (not shown), suggest-
ing that collapsin-1 is not repelling the cells in this partic-
ular motility assay.
Semaphorin III-mediated growth cone collapse is inhib-
ited by anti-NRP1 antibodies (He and Tessier-Lavigne,
1997; Kolodkin et al., 1997). A similar antibody prepa-
ration (Kolodkin et al., 1997) was tested on collapsin-
1–treated PAEC expressing NRP1 (Fig. 2 C). In the
absence of collapsin-1, the anti-NRP1 antibody had no sig-
nificant effect on the motility of either PAEC/NRP1 or
PAEC/KDR/NRP1 (Fig. 2 C, lane 2 compared with lane 1,
for each cell type). Collapsin-1 at 150 ng/ml inhibited
PAEC/NRP1 and PAEC/KDR/NRP1 motility by 55 and
65%, respectively (Fig. 2 C, lane 3 compared with lane 1,
for each cell type). However, in the presence of anti-NRP1
antibody, the inhibitory effects of 150 ng/ml collapsin-1
 
were reduced to 18 and 14% for PAEC/NRP1 and PAEC/
KDR/NRP1, respectively (Fig. 2 C, lane 4 compared with
lane 3, for each cell type). Normal rabbit IgG was ineffec-
tive in inhibiting collapsin-1 activity (not shown).
While collapsin-1 inhibited NRP1-mediated motility, it
did not inhibit DNA synthesis in PAEC/NRP1 or PAEC/
KDR/NRP1 (not shown). Lack of any inhibitory effects in
the 48-h DNA synthesis assay was taken as evidence that
the inhibition of EC motility in the 4-h motility assay was
not due to collapsin-1–mediated cell toxicity.
 
Collapsin-1 and VEGF
 
165 
 
Compete for
PAEC/KDR/NRP1 Motility, DRG Collapse, and 
Binding to NRP1 
 
Since NRP1 is a receptor for both VEGF
 
165
 
 and collapsin-1,
we wanted to test whether they would compete with each
other in affecting NRP1-mediated activities and in binding
to NRP1. First, we investigated the effects of collapsin-1
on VEGF
 
165
 
 stimulatory activity and the effects of VEGF
 
165
 
on collapsin-1 inhibitory activity (Fig. 3). VEGF
 
165
 
 is chemo-
tactic for PAEC/KDR/NRP1 (Soker et al., 1998). PAEC/
KDR/NRP1 were stimulated with increasing concentra-
tions of VEGF
 
165
 
 in the absence or presence of 150 ng/ml
collapsin-1 in a Boyden chamber motility assay (Fig. 3 A).
In the absence of collapsin-1, VEGF stimulated PAEC/
KDR/NRP1 chemotaxis in a dose-dependent manner with
a typical bell-shaped curve. However, in the presence of a
constant amount of collapsin-1 (150 ng/ml), the chemotac-
tic activity of VEGF
 
165
 
 was reduced at each concentration
of VEGF
 
165 
 
(0.1–50 ng/ml) although never totally abro-
gated. About five times more VEGF
 
165
 
 was required for
half-maximal stimulation of PAEC/KDR/NRP1 chemotaxis
when 150 ng/ml of collapsin-1 was present. In a reciprocal
experiment, the effect of increasing concentrations of col-
lapsin-1 (0–300 ng/ml) on the inhibition of PAEC/KDR/
NRP1 motility at a constant level of VEGF
 
165
 
 was tested
(Fig. 3 B). VEGF
 
165
 
 was added at 5 ng/ml, the optimal con-
centration for stimulating chemotaxis, as shown in Fig. 3 A.
Collapsin-1 inhibited both basal motility and VEGF
 
165
 
-
induced motility in a dose-dependent manner. However, in
the presence of VEGF
 
165
 
, the motility levels were higher,
about six- to sevenfold at each concentration of collapsin-1.
Figure 2. Collapsin-1 inhibits the
motility of EC expressing NRP1.
(A) PAEC, PAEC/NRP1,
PAEC/KDR, and PAEC/KDR/
NRP1 were seeded in the upper
wells of a Boyden chamber. Col-
lapsin-1 (150 ng/ml) was added
(gray bars) or not added (white
bars) to the lower wells. (B)
PAEC/NRP1 and PAEC/KDR/
NRP1 were seeded in the upper
wells and increasing concentra-
tions of collapsin-1 were added
to the lower wells of the Boyden
chamber. (C) PAEC/NRP1 and PAEC/KDR/NRP1 were cultured in complete medium and seeded in the upper wells of a Boyden
chamber. For each cell type, either 0 (lanes 1 and 2) or 150 ng/ml (lanes 3 and 4) of collapsin-1 was added in the absence (hatched bars)
or presence (solid bars) of 30 mg/ml anti-NRP1 antibodies. For each set of experiments, after a 4-h incubation, the numbers of cells that
had migrated through the filter in each field were counted. Each data point represents the mean 6 SD of four independent wells. 
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We also examined whether VEGF
 
165
 
 and collapsin-1
have competing effects on growth cone motility (Fig. 3 C).
Collapsin-1 induces the collapse and paralysis of specific
neuronal growth cones, including those growing from ex-
planted DRG (Luo et al., 1993). Increasing concentrations
of collapsin-1 normally induce collapse with a half maxi-
mal effect at 
 
z
 
3 ng/ml. However, collapsin-1 is about sev-
enfold less effective in inducing growth cone collapse
when 100 ng/ml VEGF
 
165 
 
is present. Additional assays
(data not shown) suggest that VEGF
 
165
 
 is by itself neither
an attractant nor a repellent for sensory growth cones.
 
Concentrations of VEGF
 
165
 
 up to 200 ng/ml did not induce
growth cone collapse, nor did they attract axons extending
from DRG explants embedded in a collagen/matrigel ma-
trix that contained 293T cells expressing recombinant
VEGF
 
165
 
. Thus, the ability of VEGF
 
165
 
 to reduce the effec-
tiveness of collapsin-1 is unlikely to represent the activa-
tion of a parallel VEGF
 
165
 
-mediated attractive response,
but might reflect a degree of competitive binding to NRP1.
Since collapsin-1 and VEGF
 
165 
 
compete with each other
functionally, we investigated whether they would compete
with each other for binding to NRP1. A stable COS-7 cell
line expressing NRP1 (COS-7/NRP1) was established and
incubated with increasing amounts of an AP-VEGF
 
165
 
fusion protein. AP-VEGF
 
165
 
 binds to these cells in a
dose-dependent manner (Fig. 3 D). No binding to paren-
tal  COS-7 cells occurred (not shown). Binding of AP-
VEGF
 
165
 
 to COS-7/NRP1 cells was competed 12-fold by
50 nM untagged VEGF
 
165
 
. Collapsin-1 at a concentration
of 30 nM inhibited AP-VEGF
 
165
 
–binding by 
 
z
 
10-fold.
Taken together, the functional and binding results suggest
that VEGF
 
165
 
 and collapsin-1 compete with each other for
binding sites on NRP1.
Collapsin-1 Inhibits Microvessel Outgrowth from
Aortic Rings 
The effects of collapsin-1 were tested on EC sprouting
and microvessel formation in rat aortic ring segments
that were embedded in collagen gels and maintained
in a serum-free medium that favored microvessel out-
growth (Fig. 4). As observed by phase-contrast micros-
copy, branching microvessels formed a capillary network
of tubes and loops with lumen-like structures at the pe-
riphery of the aortic rings, starting on day four and reach-
ing a maximal degree of sprouting on days 12–15 (Fig. 4, A
and B). The identity of the EC in the sprouts was con-
firmed by immunohistochemical detection of von Wille-
brand factor and by morphological analysis using EM (not
shown). When collapsin-1 (300 ng/ml) was added on day
two after embedding of the aortic rings and thereafter
every second day, the outgrowth of sprouts was strongly
inhibited (Fig. 4, C and D). A quantitative analysis dem-
onstrated that collapsin-1 inhibited microvessel EC out-
growth by 80–90% (Fig. 5). When collapsin-1 was added
into the culture medium on day two and washed away on
day four, normal outgrowth of microvessels was observed
on day 12 (Fig. 4, E and F). The reversibility of the mi-
crovessel outgrowth demonstrated that collapsin-1 inhibi-
tion of sprouting was not due to cell toxicity.
Collapsin-1 Disrupts Endothelial Cell Lamellipodia 
Formation and Cytoskeleton Organization in an
NRP1-dependent Manner 
Maintenance and physiological reorganization of the cy-
toskeleton play a crucial role in cell motility in response to
mechanical and humoral stimuli (Hall, 1998; Mackay and
Hall, 1998; Sheetz et al., 1998). RAEC sprouting from aor-
tic rings were cultured. These cells formed a typical EC
cobblestone monolayer at confluence (not shown), ex-
pressed NRP1 as demonstrated by Northern blot analysis
(Fig. 6 A), and their motility was inhibited by collapsin-1
in a dose-dependent manner with an ID50 of z10 ng/ml
Figure 3. Competition of collapsin-1 and VEGF165 for PAEC/
KDR/NRP1 motility, DRG collapse, and binding to NRP1 ex-
pressed by COS-7 cells. (A) PAEC/KDR/NRP1 motility at a con-
stant concentration of collapsin-1. Serum-starved PAEC/KDR/
NRP1 were seeded in the upper wells of a Boyden chamber. In-
creasing concentrations of VEGF165 were added to the lower
wells in the absence (white circles) or presence (black triangles)
of 150 ng/ml collapsin-1. (B) PAEC/KDR/NRP1 motility at a
constant concentration of VEGF165. Serum-starved PAEC/KDR/
NRP1 cells were seeded in the upper wells of a Boyden chamber
and increasing concentrations of collapsin-1 were added to the
lower wells in the absence (white circles) or presence (black cir-
cles) of 5 ng/ml VEGF165. After 4 h, the numbers of migrated
cells per field were counted as in Fig. 2. Each data point repre-
sents the mean 6 SD of four independent wells. (C) DRG col-
lapse. The biological activity of collapsin-1 on DRG is attenuated
by VEGF165. A growth cone collapse assay was performed in the
presence (black circles) and absence (white circles) of 100 ng/ml
recombinant VEGF165. The percentage of collapsed growth
cones extending from explanted DRG are plotted against the
concentration of recombinant collapsin-1 added to the culture.
Greater concentrations of collapsin-1 are required to achieve the
same level of collapse when VEGF165 is present. (D) Competitive
binding to COS-7/NRP1. COS-7 cells stably expressing NRP1
were incubated for 1 h with serial dilutions of CM containing AP-
VEGF165 in the absence (white circles) or presence of 30 nM (3
mg/ml) collapsin-1 (black triangles) or 50 nM (1.25 mg/ml)
VEGF165 (black circles). AP-VEGF165 bound to COS-7/NRP1
cells was measured colorimetrically at OD414.The Journal of Cell Biology, Volume 146, 1999 238
and a maximal inhibition of 60–65% at 30 ng/ml (Fig. 6 B).
However, in the presence of anti-NRP1 antibody, the in-
hibitory effects of 150 ng/ml collapsin-1 were reduced to
z18% (not shown), consistent with the inhibitory effects
of these antibodies on collapsin-1 inhibition of PAEC/
NRP1 and PAEC/KDR/NRP1 motility that was shown in
Fig. 2 C. To clarify possible mechanisms of collapsin-1 in-
hibition of EC, RAEC were seeded on fibronectin-coated
glass chamber slides, grown for one day, treated with col-
lapsin-1 (300 ng/ml) for 30 min, and analyzed by DIC optic
microscopy (Fig. 7, A–C) and phalloidin-FITC staining
(Fig. 7, D–F). RAEC typically exhibit numerous active
lamellipodia, as characterized by membrane ruffling (Fig.
7, A and D). However, in the presence of collapsin-1,
there was a significant retraction of the lamellipodia, as
shown in Fig. 7, B and E, that occurred in 30–50% of the
RAEC population. Time-lapse video microscopy showed
that these alterations in lamellipodia structures began z10
min after exposure to collapsin-1 (not shown). Within a
given responsive cell, almost of all the lamellipodia were
retracted. The cell membranes became thinner, ruffling
was undetectable, and cell surface blebs were observed.
Phalloidin-FITC staining showed that collapsin-1 treat-
ment resulted in the loss of polymerized actin fibers (Fig.
7, E compared with D). In these cells, z70–80% of the
F-actin was depolymerized. It appeared that depolymer-
ized actin was clustered in the retracted lamellipodia. The
collapsin-1 effects on RAEC morphology were abrogated
when collapsin-1 was heat-inactivated by 708C treatment
for 30 min (Fig. 7, C and F). DAPI staining of nuclei
showed no DNA breakage, indicating that collapsin-1 did
not induce apoptosis in the RAEC (Fig. 7, G–I).
To determine whether the collapsin-1 inhibition of
lamellipodia formation observed for RAEC was mediated
by NRP1, parental PAEC and PAEC expressing NRP1,
KDR, or both receptors, were treated with collapsin-1 and
analyzed by DIC optic microscopy (Fig. 8). Collapsin-1 did
not induce morphological changes in parental PAEC (Fig.
8, A versus E) or in PAEC/KDR (Fig. 8, C versus G). On
the other hand, 300 ng/ml collapsin-1 altered the morphol-
ogy of PAEC/NRP1 (Fig. 8, B versus F) and PAEC/KDR/
NRP1 (Fig. 8, D versus H), by inducing significant retrac-
tion of lamellipodia. Taken together, RAEC and PAEC
morphology analysis suggest that collapsin-1 disorganizes
EC cytoskeleton, retracts lamellipodia, and that these ef-
fects are mediated by NRP1.
Discussion
NRP1 is an unusual receptor in that it binds two structur-
ally unrelated ligands that have different biological activi-
ties. In neuronal cells, NRP1 is a receptor for members of
the semaphorin family (He and Tessier-Lavigne, 1997;
Kolodkin et al., 1997). A subset of secreted vertebrate
semaphorins repel and collapse advancing growth cones in
Figure 4. Effect of collapsin-1
on microvessel outgrowth in
vitro. Rat aortic rings were
embedded in type I collagen
gels. Serum-free endothelial
growth medium was added
and replaced every other day
with fresh medium. Micro-
vessel structure was observed
by phase microscopy on day
14 at low (A, C, and E) or
high (B, D, and F) magnifica-
tion. A and B, no addition; C
and D, collapsin-1 (300 ng/
ml) was added on day two
and every second day there-
after; E and F, collapsin-1
was added on day two and
the medium was replaced on
day four without further ad-
dition of collapsin-1.
Figure 5. Quantification of microvessel outgrowth in the pres-
ence or absence of collapsin-1. The sprouting microvessels shown
in Fig. 4, without collapsin-1 (white circles) or with 300 ng/ml col-
lapsin-1 (black circles), were counted under a phase microscope.
Each data point represents the mean 6 SD of four independent
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an NRP1-dependent manner. In EC, NRP1 is a receptor
for VEGF165, a potent angiogenesis factor (Soker et al.,
1998). Expression of NRP1 in EC enhances the ability of
VEGF165 to bind to KDR and to stimulate chemotaxis via
KDR. Thus, depending on the ligand and cell type, inter-
actions with NRP1 can lead to either inhibition or stimula-
tion of cell motility. Since EC respond to VEGF165 by en-
hanced motility, we wanted to know whether these cells
would also respond to collapsin-1 (semaphorin III), the
hypothesis being that collapsin-1 would inhibit EC motil-
ity in an NRP1-dependent manner. If collapsin-1 inhibited
EC motility, it would be possible to determine whether or
not VEGF165 and collapsin-1 could compete with each
other for an NRP1-dependent activity, such as motility, on
the same cell type. That collapsin-1 would affect EC was
not necessarily obvious, since it has been suggested that
there may be additional receptor components in neurons
that are required to mediate semaphorin activity (He and
Tessier-Lavigne, 1997; Feiner et al., 1997; Kolodkin et al.,
1997; Nakamura et al., 1998), and these putative receptors
may not be present in EC. Collapsin-1 effects on EC were
assayed on PAEC transfected with NRP1, primary cul-
tures of RAEC, and EC sprouting from aortic segments
embedded in collagen gels. It was found that collapsin-1
was an effective inhibitor of EC motility as follows: first,
collapsin-1 bound only to PAEC expressing NRP1. Sec-
ond, collapsin-1 inhibited the motility of PAEC expressing
NRP1, but not the motility of parental PAEC or PAEC
expressing KDR alone. The motility of PAEC/NRP1 and
PAEC/KDR/NRP1, but not parental PAEC or PAEC/
KDR, was inhibited by up to 60–70%, and the inhibition
was abrogated by anti-NRP antibodies. The inhibition of
EC motility, as assayed in the Boyden chamber, did not
appear to be due to collapsin-1–mediated chemorepulsion.
Third, collapsin-1 inhibited the motility of primary RAEC,
which express NRP1, by up to 50–60%, and this effect was
abrogated by anti-NRP1 antibodies. Fourth, collapsin-1
inhibited by 80–90%, microvessel outgrowth and sprout-
ing (in vitro angiogenesis) from rat aortic segments em-
bedded in collagen. And fifth, collapsin-1 altered cell mor-
phology markedly. As revealed by DIC optic microscopy,
the addition of collapsin-1 resulted in the retraction of
lamellipodia within minutes. Phalloidin-FITC staining dem-
onstrated substantial loss of polymerized F-actin stress
fibers in lamellipodia that are composed of a compact net-
work of actin filaments. The changes in morphology were
NRP1 dependent and did not occur in parental PAEC or
PAEC/KDR. Nor did these changes occur when collapsin-1
was heat-inactivated. The collapsin-1 inhibitory effects on
EC motility did not appear to be due to toxicity. For exam-
ple, in the presence of collapsin-1 at relatively high con-
centrations, the motility of PAEC was inhibited only if
they expressed NRP1. Basal DNA synthesis in PAEC was
not inhibited in a 48-h assay. The inhibitory effects on EC
outgrowth and sprouting from aortic segments were re-
versible by washing away the collapsin-1 after 48 h. DAPI
staining of RAEC after collapsin-1 treatment showed in-
tact nuclei. Taken together, these results demonstrate that
collapsin-1 interacts with NRP1 in a functional manner in
nonneuronal cells. Whether NRP1 alone is sufficient to
Figure 6. Collapsin-1 inhibits the motility of RAEC. RAEC were
isolated from rat aortas as described in Materials and Methods
and were cultured in DME containing 10% FCS and FGF-2 (1
ng/ml). (A) Northern blot analysis of total RAEC RNA with 32P-
labeled rat NRP1 cDNA as a probe. Arrow indicates the position
of rat NRP1. (B) The RAEC were seeded in the upper wells of a
Boyden chamber and increasing concentrations of collapsin-1
were added to the lower wells. After 4 h, the number of migrated
cells per field was counted as in Fig. 2. Each data point represents
the mean 6 SD of four independent wells.
Figure 7. Collapsin-1 alters RAEC morphology. RAEC were
seeded in 8-well culture slides precoated with fibronectin. The
next day, medium was replaced with fresh medium (A, D, and
G), medium containing 300 ng/ml collapsin-1 (B, E, and H), and
medium containing 300 ng/ml collapsin-1 preheated at 708C for
30 min (C, F, and I). After 30 min of incubation with or without
collapsin-1, cells were fixed. (A–C) Analysis by DIC optic mi-
croscopy. (D–F) Staining with phalloidin-FITC and analysis by
fluorescence microscopy. (G–I) The cells in D–F were stained for
DNA with DAPI. The cells in A–C are not the same as those in
D–F, because different fixation methods were used.The Journal of Cell Biology, Volume 146, 1999 240
mediate a full inhibition of EC motility by collapsin-1 is
unclear. The motility of EC was inhibited maximally by
65–80%. There may be another collapsin receptor or core-
ceptor present in neuronal cells, but not EC that are
needed to mediate full inhibition by collapsin-1. Other
semaphorin receptors do exist, for example, plexin A is a
receptor for semaphorin I (Winberg et al., 1998), and there
may be other novel receptors as well.
Semaphorins and VEGF165 both bind to NRP1 when ex-
pressed by EC, but do they compete for the same binding
sites? The extracellular domain of NRP1 consists of sev-
eral subdomains (Takagi et al., 1995; Kawakami et al.,
1996). These include two complement C1r/s homology-
binding (CUB) domains, two domains homologous to the
C1 and C2 domains of coagulation factor V and VIII, and
a 170-amino acid MAM-homology domain (also known as
the a, b, and c domains, respectively). In one report using
full-length Sema D (Sema III), it was concluded that the
CUB domain was the primary semaphorin binding site,
with some contribution of the coagulation factor homol-
ogy domain (Nakamura et al., 1998). Another report, us-
ing NRP1 deletion analysis, indicated that the CUB and
coagulation factor domains of NRP1 were necessary and
sufficient for binding of the semaphorin III (sema) domain
whereas the coagulation factor domains alone were neces-
sary and sufficient for binding the Sema III Ig-basic do-
main (Giger et al., 1998). The coagulation factor homology
domain alone was responsible for binding 125I-VEGF165.
Furthermore, the Ig-basic ligand competitively inhibited
the binding of 125I-VEGF165 to NRP1, suggesting that the
Sema III Ig-basic domain and VEGF bind to similar sites.
Our own studies indicate that full-length collapsin-1 inhib-
its the binding of a VEGF165 fusion protein to COS-7 cells
expressing NRP1. However, these results are based on
binding assays and might not reflect what might happen in
a functional assay. In our competition assays analyzing ef-
fects on PAEC/KDR/NRP1 motility, the dose-dependent
chemotactic activity of VEGF165 was reduced at each con-
centration of collapsin-1, although not totally abrogated.
About five times more VEGF165 was required for half
maximal stimulation of PAEC/KDR/NRP1 chemotaxis
when collapsin-1 was present. In a reciprocal experiment,
in which collapsin-1 inhibited basal motility in a dose-
dependent manner, the motility levels were higher in the
presence of constant VEGF165, about six- to sevenfold at
each concentration of collapsin-1. In the DRG collapse as-
say, collapsin-1 was about sevenfold less effective in induc-
ing growth cone collapse when constant VEGF165 was
present. In addition, the binding of a VEGF165 alkaline
phosphatase fusion protein to COS cells expressing NRP1
was inhibited by collapsin-1. Taken together, these results
suggest that VEGF165 and collapsin-1 compete with each
other to some degree for binding sites on NRP1, but where
the exact sites of overlap are and whether the two ligands
have similar affinities for these binding sites needs to be
determined.
Although both collapsin-1 and VEGF165 bind to similar
sites on NRP1, they appear to have different signaling
mechanisms. VEGF165 is a chemoattractant for PAEC ex-
pressing both NRP1 and KDR, but not for PAEC express-
ing NRP1 alone (Soker et al., 1998). It appears that the
chemotactic activity of VEGF165 is mediated primarily via
KDR with NRP1 acting as a coreceptor that enhances
chemotactic activity by an as yet unknown mechanism. On
the other hand, collapsin-1 inhibits the migration of EC
expressing NRP1 alone, and to the same extent, as EC ex-
pressing both NRP1 and KDR. Thus, it appears that col-
lapsin-1 signals via NRP1 directly to act as an inhibitor of
EC migration without the involvement of KDR. However,
some other, as yet unidentified, collapsin-1 receptor may
be involved.
There are some similarities in the effects of collapsin-1
on neuronal cell growth cones and EC morphology. Actin
is one of the major cytoskeletal components of growth
cones. F-actin is preferentially polymerized at the growth
cone’s leading edge. Directional growth in response to ex-
ternal cues is achieved by stabilizing and destabilizing the
actin cytoskeleton in lamellipodia and filopodia (Luo et al.,
1997). Treatment with collapsin induces a net loss of poly-
merized F-actin at the leading edges of the growth cones.
In EC, collapsin-1 treatment results in rapid retraction of
lamellipodia and substantial loss of polymerized F-actin
stress fibers. Whether filopodia are affected is not clear
because the EC used in our experiments have relatively
few of these structures. Our results suggest that analogous
Figure 8. Collapsin-1 alters the morphology only of EC express-
ing NRP1. PAEC (A and E), PAEC/NRP1 (B and F), PAEC/
KDR (C and G), and PAEC/KDR/NRP1 (D and H) were incu-
bated for 30 min in the absence (A–D) or presence (E–H) of 300
ng/ml collapsin-1, fixed, and analyzed by DIC optic microscopy
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to its effects on the growth cone cytoskeleton, collapsin-1
induces the collapse of the EC cytoskeleton.
NRP1, a receptor expressed by both neuronal cells and
EC that can bind both collapsin-1 and VEGF165, might
provide a molecular connection between the motility
events that occur in neuronal guidance and angiogenesis.
In embryonic development and adults, there is a close spa-
tial relationship between neurons and blood vessels, and it
is possible that there are factors, e.g., collapsin/semaphor-
ins, that regulate both neuronal guidance and angiogene-
sis. In support of this speculation, a recent report has dem-
onstrated that another set of repulsive neuronal guidance
factors, the ephrins and their receptors, the ephs, are in-
volved in angiogenesis (Wang et al., 1998; Yancopoulos et al.,
1998). During mouse development, ephrin-B2 is a marker
for arterial EC and Eph-B4 is a marker for venous EC.
Ephrin-B2 knockout mice display defects in angiogenesis
(Wang et al., 1998), as do NRP1 knockouts (Kitsukawa
et al., 1997). Future investigations will determine the ex-
tent of cross-talk between angiogenesis and neuronal guid-
ance.
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